Kathryn B. Horwitz, PhD
Discovering ways to improve treatment response in patients with estrogen receptor-positive breast cancer.
Breast cancers that are driven by estrogen—called estrogen receptor (ER)-positive, have the best five-year prognosis of any breast cancer. Despite effective therapies to treat ER-positive breast cancer, one-quarter to one-third of patients will experience a breast cancer recurrence. The goal of Drs. Horwitz’s and Sartorius’ BCRF research is to identify and test vulnerabilities in a common but understudied group of cells in ER-positive tumors that are ER-negative. This population of cells may be responsible for drug resistance and recurrence and behaves like cancer stem cells, which can initiate and drive cancer progression. By understanding how these cells promote tumor growth and identifying their weaknesses, they hope to identify strategies to turn them off and prevent recurrence.
In the last year, Drs. Horwitz and Sartorius finished developing endocrine and drug resistant variants of ER-positive breast cancer from their new breast cancer model system. The team has identified prospective mechanisms for expansion of ER-negative “stem cell” populations that may drive tumor progression and have found that these cells often increase in number during the course of hormonal therapies, can adapt to the stress of long-term exposure to hormone therapies, and can interact with other cells that enable their travel through the bloodstream to form sites of metastases.
The team will use their ER-positive breast cancer model to address mechanisms of ER-negative cells in tumors and metastasis. Their goal is to identify how long-term estrogen-targeting therapies impact the ER-negative “stem cell” population in tumors to promote metastasis.
Kathryn B. Horwitz, PhD joined the faculty at the University of Colorado after undergraduate studies at Barnard College, graduate studies at the UT Southwestern Medical School and postdoctoral work at UT San Antonio.
Research in her laboratory is both basic and translational. It focuses on the role of women’s hormones – estradiol and progesterone – and their receptors, on luminal breast cancer cell heterogeneity, growth, treatment, metastasis and stem cells. Her lab has extensive expertise in molecular and tumor-cell biology, using in vitro and in vivo models and clinical samples. Long-term goals are to improve the strategies and outcomes of therapies for luminal disease. Research topics include: transcriptional mechanisms of progesterone receptors; epigenetic and post-transcriptional receptor modifications and signaling cross-talk; hormones in cancer growth; mechanisms of resistance to endocrine therapies; hormones and regulation of breast cancer stem cells; intratumoral cell heterogeneity in luminal disease; hormonal regulation of metastasis and the stromal microenvironment; development of new breast cancer models, and translation of laboratory findings into clinical practice.
She has mentored numerous trainees who hold senior faculty posts at many US medical centers. She is a well-known national and international scholar, has served on multiple society boards, study sections and editorial boards, was elected President of the Endocrine Society, received its Fred Conrad Koch Award for exceptional contributions to endocrinology, and recently received the National Cancer Institute’s Rosalind E. Franklin Award for commitment to cancer research.
When you give to BCRF, you're funding critical hours in the lab. More time for research means longer, healthier lives for the ones we love.